Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis

被引：9

作者：

Stolze, T. ^{[1
]}

Franke, S. ^{[2
]}

Haybaeck, J. ^{[2
,3
,4
]}

Moehler, M. ^{[5
]}

Grimminger, P. P. ^{[6
]}

Lang, H. ^{[6
]}

Roth, W. ^{[7
]}

Gockel, I ^{[8
,9
]}

Kreuser, N. ^{[8
,9
]}

Blaker, H. ^{[10
]}

Wittekind, C. ^{[10
]}

Lordick, F. ^{[11
]}

Vieth, M. ^{[12
]}

Veits, L. ^{[12
]}

Waidmann, O. ^{[13
,14
]}

Lingohr, P. ^{[15
]}

Peitz, U. ^{[16
]}

Schildberg, C. ^{[17
]}

Kruschewski, M. ^{[18
]}

Vassos, N. ^{[19
]}

Goni, E. ^{[20
]}

Bruns, C. J. ^{[21
]}

Ridwelski, K. ^{[22
,23
]}

Wolff, S. ^{[24
]}

Lippert, H. ^{[23
,24
]}

Schumacher, J. ^{[25
]}

Malfertheiner, P. ^{[1
,20
]}

Venerito, M. ^{[1
]}

机构：

[1] Otto von Guericke Univ Hosp Magdeburg, Dept Gastroenterol Hepatol & Infect Dis, Leipziger Str 66, D-39120 Magdeburg, Germany

[2] Otto von Guericke Univ Hosp Magdeburg, Inst Pathol, Magdeburg, Germany

[3] Med Univ Innsbruck, Inst Pathol Neuropathol & Mol Pathol, Innsbruck, Austria

[4] Med Univ Graz, Diagnost & Res Ctr Mol BioMed, Inst Pathol, Graz, Austria

[5] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Mainz, Germany

[6] Johannes Gutenberg Univ Mainz, Dept Gen Visceral & Transplant Surg, Mainz, Germany

[7] Univ Hosp Mainz, Inst Pathol, Mainz, Germany

[8] Leipzig Univ Med Ctr, Dept Med 2, Leipzig, Germany

[9] Leipzig Univ Med Ctr, Univ Canc Ctr Leipzig UCCL, Leipzig, Germany

[10] Univ Hosp Leipzig, Inst Pathol, Leipzig, Germany

[11] Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany

[12] Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Klinikum Bayreuth, Bayreuth, Germany

[13] Univ Hosp Frankfurt, Dept Internal Med 1, Main Area Gastroenterol & Hepatol, Frankfurt, Germany

[14] Univ Hosp Frankfurt, Univ Canc Ctr, Frankfurt, Germany

[15] Univ Hosp Bonn, Dept Gen Visceral Thorac & Vasc Surg, Bonn, Germany

[16] Raphaelshosp, Dept Gastroenterol, Munster, Germany

[17] Brandenburg Univ Hosp Visceral Surg, Dept Gen & Visceral Surg, Brandenburg, Germany

[18] Hosp Frankfurt Oder, Dept Gen & Visceral Surg, Frankfurt, Germany

[19] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Surg, Div Surg Oncol & Thorac Surg, Mannheim, Germany

[20] Ludwig Maximilians Univ Munchen, Dept Med 2, Univ Hosp, Munich, Germany

[21] Univ Hosp Cologne, Dept Gen Tumor & Transplantat Surg, Cologne, Germany

[22] Municipal Hosp, Dept Gen & Visceral Surg, Magdeburg, Germany

[23] Otto von Guericke Univ Hosp, AN Inst Qual Assurance Operat Med, Magdeburg, Germany

[24] Otto von Guericke Univ Hosp, Dept Gen Visceral Vasc & Transplantat Surg, Magdeburg, Germany

[25] Philipps Univ Marburg, Human Genet Ctr, Marburg, Germany

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 03期

关键词：

Gastric cancer; Mismatch repair deficiency; Chemotherapy; Survival; Meta-analysis; EPSTEIN-BARR-VIRUS; MICROSATELLITE INSTABILITY; PROGNOSTIC VALUE; CARCINOMA; ACTIVATION; DIAGNOSIS; THERAPY; RISK;

D O I：

10.1007/s00432-022-03953-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose In a post hoc analysis of the MAGIC trial, patients with curatively resected gastric cancer (GC) and mismatch repair (MMR) deficiency (MMRd) had better median overall survival (OS) when treated with surgery alone but worse median OS when treated with additional chemotherapy. Further data are required to corroborate these findings. Methods Between April 2013 and December 2018, 458 patients with curatively resected GC, including cancers of the esophagogastric junction Siewert type II and III, were identified in the German centers of the staR consortium. Tumor sections were assessed for expression of MLH1, MSH2, MSH6 and PMS2 by immunohistochemistry. The association between MMR status and survival was assessed. Similar studies published up to January 2021 were then identified in a MEDLINE search for a meta-analysis. Results MMR-status and survival data were available for 223 patients (median age 66 years, 62.8% male), 23 patients were MMRd (10.3%). After matching for baseline clinical characteristics, median OS was not reached in any subgroup. Compared to perioperative chemotherapy, patients receiving surgery alone with MMRd and MMRp had a HR of 0.67 (95% CI 0.13-3.37, P = 0.63) and 1.44 (95% CI 0.66-3.13, P = 0.36), respectively. The meta-analysis included pooled data from 385 patients. Compared to perioperative chemotherapy, patients receiving surgery alone with MMRd had an improved OS with a HR of 0.36 (95% CI 0.14-0.91, P = 0.03), whereas those with MMRp had a HR of 1.18 (95% CI 0.89-1.58, P = 0.26). Conclusion Our data support a positive prognostic effect for MMRd in GC patients treated with surgery only and a differentially negative prognostic effect in patients treated with perioperative chemotherapy. MMR status determined by preoperative biopsies may be used as a predictive biomarker to select patients for perioperative chemotherapy in curatively resectable GC.

引用

页码：1007 / 1017

页数：11

共 50 条

[21] Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
Yao, Anqi
Wang, You
Peng, Xiaohong
Ye, Rong
Wang, Qiaoli
Qi, Yuexiao
Zhou, Fuxiang
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (12) : 2107 - 2117
[22] Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis
Gray, Ronan T.
Coleman, Helen G.
Hughes, Carmel
Murray, Liam J.
Cardwell, Chris R.
CANCER EPIDEMIOLOGY, 2016, 45 : 71 - 81
[23] Perioperative versus adjuvant chemotherapy for resectable gastric cancer: a meta-analysis of randomized controlled trials
Ou, Haiya
Zhuang, Jiamei
Jian, Mingwei
Zheng, Xinyi
Wu, Tingping
Cheng, Honghui
Qian, Rui
FRONTIERS IN ONCOLOGY, 2025, 15
[24] Efficacy of Chemoimmunotherapy versus Chemotherapy for Gastric Cancer: A Meta-Analysis of Survival Outcomes
Xie, Juan
Chen, Lin
Liu, Qing
Li, Xi-Tai
Lei, Xiao-Yong
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (18) : 2649 - 2660
[25] The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis
Atwal, Amit
Snowsill, Tristan
Dandy, Marcus Cabrera
Krum, Thomas
Newton, Claire
Evans, Dafydd Gareth
Crosbie, Emma J.
Ryan, Neil A. J.
INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (09) : 1626 - 1639
[26] Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study
Zhao, Lulu
Fu, Yongliang
Niu, Penghui
Zhang, Fan
Jiao, Fuzhi
Zhou, Xiadong
Wu, Zhenkun
Wang, Wanqing
Luan, Xiaoyi
Han, Xue
He, Mingyan
Guan, Quanlin
Li, Yumin
Zhao, Dongbing
Gao, Jidong
Chen, Yingtai
ONCOLOGIST, 2023, 28 (10) : e891 - e901
[27] Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis
Han, Jinmin
Wang, Zhongtang
Liu, Chengxin
FUTURE ONCOLOGY, 2021, 17 (17) : 2257 - 2274
[28] Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis
Wei, Chenyu
Du, Xuelin
Hu, Jiexuan
Dong, Yin
Chen, Yan
Cao, Bangwei
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
[29] Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta-analysis
Hu, Guoming
Zhong, Kefang
Wang, Songxiang
Wang, Shimin
Ding, Qiannan
Xu, Feng
Chen, Wei
Cheng, Pu
Huang, Liming
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1747 - 1756
[30] Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis
Petrelli, Fausto
Zaniboni, Alberto
Ghidini, Antonio
Ghidini, Michele
Turati, Luca
Pizzo, Claudio
Ratti, Margherita
Libertini, Michela
Tomasello, Gianluca
CANCERS, 2019, 11 (04)

← 1 2 3 4 5 →